Select country change
Shopping cart (0 , 0,00 ) Menu Search
Manufactured by BioVendor

Annexin A1 Human, Rabbit Polyclonal Antibody

  • Regulatory status:RUO
  • Type:Polyclonal Antibody
  • Other names:Annexin I, Annexin-1, Calpactin II, Calpactin-2, Chromobindin-9, Lipocortin I, Phospholipase A2 inhibitory protein, p35, ANXA1, ANX1, LPC1
  • Species:Human
Please select your region to see available products and prices.
Cat. No. Size Price


RD181371100 0.1 mg
PubMed Product Details
Technical Data

Type

Polyclonal Antibody

Applications

Western blotting, ELISA, Immunohistochemistry

Antibodies Applications

Source of Antigen

E. coli

Hosts

Rabbit

Preparation

The antibody was raised in rabbits by immunization with the recombinant Human Annexin A1.

Amino Acid Sequence

Total 355 AA. MW: 39.8 kDa (calculated). UniProtKB acc.no. P04083 (Ala2-Asn346). N-terminal His-tag (10 extra AA). Protein identity confirmed by LC-MS/MS.

MKHHHHHHASAMVSEFLKQAWFIENEEQEYVQTVKSSKGGPGSAVSPYPTFNPSSDVAALHKAIMVKGVDEATIIDILTKRNNAQRQQIKAAYLQETGKPLDETLKKALTGHLEEVVLALLKTPAQFDADELRAAMKGLGTDEDTLIEILASRTNKEIRDINRVYREELKRDLAKDITSDTSGDFRNALLSLAKGDRSEDFGVNEDLADSDARALYEAGERRKGTDVNVFNTILTTRSYPQLRRVFQKYTKYSKHDMNKVLDLELKGDIEKCLTAIVKCATSKPAFFAEKLHQAMKGVGTRHKALIRIMVSRSEIDMNDIKAFYQKMYGISLCQAILDETKGDYEKILVALCGGN

Species Reactivity

Human. Not yet tested in other species.

Purification Method

Immunoaffinity chromatography on a column with immobilized recombinant Human Annexin A1.

Antibody Content

0.1 mg (determined by BCA method, BSA was used as a standard)

Formulation

The antibody is lyophilized in 0.05 M phosphate buffer, 0.1 M NaCl, pH 7.2. AZIDE FREE.

Reconstitution

Add 0.1 ml of deionized water and let the lyophilized pellet dissolve completely. Slight turbidity may occur after reconstitution, which does not affect activity of the antibody. In this case clarify the solution by centrifugation.

Shipping

At ambient temperature. Upon receipt, store the product at the temperature recommended below.

Storage/Expiration

The lyophilized antibody remains stable and fully active until the expiry date when stored at –20°C. Aliquot the product after reconstitution to avoid repeated freezing/thawing cycles and store frozen at –80°C. Reconstituted antibody can be stored at 4°C for a limited period of time; it does not show decline in activity after one week at 4°C.

Quality Control Test

Indirect ELISA – to determine titer of the antibody SDS PAGE – to determine purity of the antibody

Note

This product is for research use only.

Summary

Research topic

Apoptosis, Atherosclerosis, Autoimmunity, Cardiovascular disease, Diabetology - Other Relevant Products, Immune Response, Infection and Inflammation, Neural tissue markers, Oncology, Renal disease, Neurodegenerative disease

Summary

Annexin A1 binds phospholipids and up to four calcium ions. It supports membrane fusion and takes part in exocytosis. It controles phospholipase A2 activity.

Summary References (12)

References to Annexin A1

  • Ansari J, Kaur G, Gavins FNE. Therapeutic Potential of Annexin A1 in Ischemia Reperfusion Injury. Int J Mol Sci. 2018 Apr 16;19(4). pii: E1211. doi:10.3390/ijms19041211. Review. PubMed PMID: 29659553; PubMed Central PMCID:PMC5979321. See more on PubMed
  • de Jong R, Leoni G, Drechsler M, Soehnlein O. The advantageous role of annexinA1 in cardiovascular disease. Cell Adh Migr. 2017 May 4;11(3):261-274. doi:10.1080/19336918.2016.1259059. Epub 2016 Nov 18. Review. PubMed PMID: 27860536;PubMed Central PMCID: PMC5479459. See more on PubMed
  • Drechsler M, de Jong R, Rossaint J, Viola JR, Leoni G, Wang JM, Grommes J,Hinkel R, Kupatt C, Weber C, Döring Y, Zarbock A, Soehnlein O. Annexin A1counteracts chemokine-induced arterial myeloid cell recruitment. Circ Res. 2015Feb 27;116(5):827-35. doi: 10.1161/CIRCRESAHA.116.305825. Epub 2014 Dec 17.PubMed PMID: 25520364. See more on PubMed
  • Gussenhoven R, Klein L, Ophelders DRMG, Habets DHJ, Giebel B, Kramer BW,Schurgers LJ, Reutelingsperger CPM, Wolfs TGAM. Annexin A1 as NeuroprotectiveDeterminant for Blood-Brain Barrier Integrity in Neonatal Hypoxic-IschemicEncephalopathy. J Clin Med. 2019 Jan 24;8(2). pii: E137. doi: 10.3390/jcm8020137.PubMed PMID: 30682787; PubMed Central PMCID: PMC6406389. See more on PubMed
  • Ka SM, Tsai PY, Chao TK, Yang SM, Hung YJ, Chen JS, Shui HA, Chen A. Urineannexin A1 as an index for glomerular injury in patients. Dis Markers.2014;2014:854163. doi: 10.1155/2014/854163. Epub 2014 Jan 20. PubMed PMID:24591769; PubMed Central PMCID: PMC3925619. See more on PubMed
  • McArthur S, Cristante E, Paterno M, Christian H, Roncaroli F, Gillies GE,Solito E. Annexin A1: a central player in the anti-inflammatory andneuroprotective role of microglia. J Immunol. 2010 Nov 15;185(10):6317-28. doi:10.4049/jimmunol.1001095. Epub 2010 Oct 20. PubMed PMID: 20962261; PubMed CentralPMCID: PMC3145124. See more on PubMed
  • Purvis GSD, Collino M, Loiola RA, Baragetti A, Chiazza F, Brovelli M, SheikhMH, Collotta D, Cento A, Mastrocola R, Aragno M, Cutrin JC, Reutelingsperger C,Grigore L, Catapano AL, Yaqoob MM, Norata GD, Solito E, Thiemermann C.Identification of AnnexinA1 as an Endogenous Regulator of RhoA, and Its Role inthe Pathophysiology and Experimental Therapy of Type-2 Diabetes. Front Immunol.2019 Mar 27;10:571. doi: 10.3389/fimmu.2019.00571. eCollection 2019. PubMed PMID:30972066; PubMed Central PMCID: PMC6446914. See more on PubMed
  • Purvis GSD, Chiazza F, Chen J, Azevedo-Loiola R, Martin L, Kusters DHM,Reutelingsperger C, Fountoulakis N, Gnudi L, Yaqoob MM, Collino M, Thiemermann C,Solito E. Annexin A1 attenuates microvascular complications through restorationof Akt signalling in a murine model of type 1 diabetes. Diabetologia. 2018Feb;61(2):482-495. doi: 10.1007/s00125-017-4469-y. Epub 2017 Oct 30. PubMed PMID:29085990; PubMed Central PMCID: PMC6448955. See more on PubMed
  • Purvis GSD, Solito E, Thiemermann C. Annexin-A1: Therapeutic Potential inMicrovascular Disease. Front Immunol. 2019 Apr 30;10:938. doi:10.3389/fimmu.2019.00938. eCollection 2019. Review. PubMed PMID: 31114582; PubMedCentral PMCID: PMC6502989. See more on PubMed
  • Qin C, Yang YH, May L, Gao X, Stewart AG, Tu Y, Woodman OL, Ritchie RH.Cardioprotective potential of annexin-A1 mimetics in myocardial infarction.Pharmacol Ther. 2015 Apr;148:47-65. doi: 10.1016/j.pharmthera.2014.11.012. Epub2014 Nov 25. Review. PubMed PMID: 25460034. See more on PubMed
  • Qin CX, Rosli S, Deo M, Cao N, Walsh J, Tate M, Alexander AE, Donner D,Horlock D, Li R, Kiriazis H, Lee MKS, Bourke JE, Yang Y, Murphy AJ, Du XJ, GaoXM, Ritchie RH. Cardioprotective Actions of the Annexin-A1 N-Terminal Peptide,Ac(2-26), Against Myocardial Infarction. Front Pharmacol. 2019 Apr 3;10:269. doi:10.3389/fphar.2019.00269. eCollection 2019. PubMed PMID: 31001111; PubMed CentralPMCID: PMC6457169. See more on PubMed
  • Sheikh MH, Solito E. Annexin A1: Uncovering the Many Talents of an OldProtein. Int J Mol Sci. 2018 Mar 31;19(4). pii: E1045. doi: 10.3390/ijms19041045.Review. PubMed PMID: 29614751; PubMed Central PMCID: PMC5979524. See more on PubMed
Related Products Docs